$1.61
4.89% today
NYSE, Feb 05, 04:23 pm CET
ISIN
US35168W1036
Symbol
GUTS
Sector
Industry

Fractyl Health Stock price

$1.54
-0.53 25.49% 1M
-0.72 31.78% 6M
-0.53 25.49% YTD
-9.57 86.17% 1Y
-13.47 89.77% 3Y
-13.47 89.77% 5Y
-13.47 89.77% 10Y
NYSE, Closing price Tue, Feb 04 2025
-0.17 9.71%
ISIN
US35168W1036
Symbol
GUTS
Sector
Industry

Key metrics

Market capitalization $73.83m
Enterprise Value $52.10m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 521.00
P/S ratio (TTM) P/S ratio 738.30
P/B ratio (TTM) P/B ratio 1.47
Revenue (TTM) Revenue $100.00k
EBIT (operating result TTM) EBIT $-81.30m
Free Cash Flow (TTM) Free Cash Flow $-60.75m
Cash position $84.66m
EPS (TTM) EPS $-6.16
P/E forward negative
P/S forward 1,476.60
EV/Sales forward 1,042.00
Short interest 11.10%
Show more

Is Fractyl Health a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Fractyl Health Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Fractyl Health forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Fractyl Health forecast:

Buy
100%

Financial data from Fractyl Health

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.10 0.10
-
100%
- Direct Costs 0.54 0.54
-
540%
-0.45 -0.45
-
-450%
- Selling and Administrative Expenses 20 20
-
20,010%
- Research and Development Expense 60 60
-
60,360%
-81 -81
-
-80,810%
- Depreciation and Amortization 0.49 0.49
-
490%
EBIT (Operating Income) EBIT -81 -81
-
-81,302%
Net Profit -63 -63
-
-62,900%

In millions USD.

Don't miss a Thing! We will send you all news about Fractyl Health directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fractyl Health Stock News

Neutral
GlobeNewsWire
5 days ago
Prioritizing Revita's clinical development on weight maintenance post-GLP-1 withdrawal in response to significant patient and physician demand in ongoing REMAIN-1 pivotal study; anticipate midpoint data analysis in Q2 2025 and full pivotal study enrollment in summer 2025
Neutral
GlobeNewsWire
about 2 months ago
RJVA-001 was successfully delivered in large animal Yucatan pig models at low total viral dose Results confirm ability to directly target pancreas with novel delivery catheter and route of administration Local delivery of RJVA-001 achieved therapeutically relevant GLP-1 expression within pancreatic beta cells with no adverse safety effects observed Company plans to initiate first-in-human studi...
Neutral
GlobeNewsWire
about 2 months ago
BURLINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced it will present new preclinical data from its Rejuva platform at the 2024 Poster Session of the 22nd World Congress Insulin Resistance, Diabetes...
More Fractyl Health News

Company Profile

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Head office United States
CEO Harith Rajagopalan
Founded 2010
Website www.fractyl.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today